Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers Sells 6,983 Shares of Stock

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the sale, the executive vice president now directly owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Wendy Carruthers also recently made the following trade(s):

• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39.

Boston Scientific Stock Up 0.2 %

NYSE:BSX opened at $76.55 on Wednesday. The firm’s 50 day simple moving average is $75.01 and its 200 day simple moving average is $67.81. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. Boston Scientific Co. has a one year low of $48.35 and a one year high of $77.99. The company has a market cap of $112.30 billion, a PE ratio of 64.33, a P/E/G ratio of 2.65 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, topping the consensus estimate of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion for the quarter, compared to the consensus estimate of $3.68 billion. On average, research analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. First Foundation Advisors bought a new position in Boston Scientific during the 1st quarter worth approximately $25,000. Eagle Bay Advisors LLC raised its holdings in Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 309 shares during the last quarter. RiverPark Advisors LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $30,000. Northwest Investment Counselors LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $31,000. Finally, YHB Investment Advisors Inc. bought a new position in Boston Scientific during the 1st quarter worth approximately $32,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Royal Bank of Canada upped their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Barclays increased their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Citigroup increased their price target on shares of Boston Scientific from $85.00 to $87.00 and gave the company a “buy” rating in a research note on Wednesday, May 22nd. UBS Group increased their price target on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $77.41.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.